Dr. Reddy’s Laboratories is making a significant move into the hormone replacement therapy (HRT) market by acquiring the Progynova and Cyclo-Progynova brands from Mercury Pharma Group for $32.15 million. This acquisition enhances the Hyderabad-based company’s portfolio and positions it strategically within a growing segment of the pharmaceutical industry.
Understanding Progynova and Cyclo-Progynova
Progynova, which contains estradiol valerate, is designed to treat symptoms associated with estrogen deficiency and to prevent post-menopausal osteoporosis. In contrast, Cyclo-Progynova combines estradiol valerate with norgestrel, providing a dual approach to HRT. This combined formulation addresses estrogen deficiency while also delivering progestogen benefits.
Market Leadership and Brand Recognition
Progynova stands out as the leading brand within the estradiol segment in India, boasting strong recognition among healthcare professionals. According to data from IQVIA for December 2025, Progynova achieved impressive sales figures of ₹100 crore, underscoring its dominance in the market. This acquisition not only reinforces Dr. Reddy’s existing gynecological offerings but also marks its strategic entry into the HRT sector.
Strategic Implications for Dr. Reddy’s Laboratories
The acquisition is a pivotal step in expanding Dr. Reddy’s market share in the HRT domain. M.V. Ramana, the Chief Executive Officer for Branded Markets in India and Emerging Markets, emphasized the significance of this move. He stated that it serves as the foundation for further growth in the HRT segment, which aligns with the company’s commitment to enhancing women’s health solutions.
Enhanced Market Access and Patient Care
Dr. Reddy’s Laboratories is well-positioned to leverage its established market access to maximize the impact of the acquired brands. Ramana noted that the company aims to bring this first-in-class treatment closer to patients, reaffirming its dedication to innovation and patient-centric care. This acquisition is more than just a financial transaction; it represents a commitment to improving health outcomes for women dealing with the effects of menopause.
The Future of HRT in India
As the demand for hormone replacement therapy grows, Dr. Reddy’s strategic entry into this market segment comes at a crucial time. The acquisition of Progynova and Cyclo-Progynova allows the company to meet increasing patient needs while reinforcing its position as a leader in gynecological health.
Conclusion: A Promising Horizon
In summary, Dr. Reddy’s Laboratories’ acquisition of Progynova and Cyclo-Progynova marks a significant milestone in the company’s growth strategy. By entering the hormone replacement therapy market, Dr. Reddy’s not only enhances its product portfolio but also reinforces its commitment to improving women’s health in India. This strategic move promises to deliver impactful solutions to patients and solidify the company’s role as a key player in the pharmaceutical landscape.
- Dr. Reddy’s Laboratories acquires Progynova and Cyclo-Progynova for $32.15 million.
- Progynova is the top brand in the estradiol segment in India.
- The acquisition strengthens Dr. Reddy’s gynecological portfolio and market presence.
- The company aims to enhance patient care through innovative health solutions.
- This move reflects a growing demand for hormone replacement therapies in the Indian market.
Read more → www.thehindubusinessline.com